The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Open accessAbstract
Class I histone deacetylases (HDACs) are promising targets for epigenetic therapies for a range of diseases such as cancers, inflammations, infections and neurological diseases. Although six HDAC inhibitors are now licensed for clinical treatments, they are all pan-inhibitors with little or no HDAC isoform selectivity, exhibiting undesirable side effects. A major issue with the currently available HDAC inhibitors is that they have limited specificity and target multiple deacetylases. Except for HDAC8, Class I HDACs (1, 2 and 3) are recruited to large multiprotein complexes to function. Therefore, there are rising needs to develop new, hopefully, therapeutically efficacious HDAC inhibitors with isoform or complex selectivity. Here, upon the introduction of the structures of Class I HDACs and their complexes, we provide an up-to-date overview of the structure-based discovery of Class I HDAC inhibitors, including pan-, isoform-selective and complex-specific inhibitors, aiming to provide an insight into the discovery of additional HDAC inhibitors with greater selectivity, specificity and therapeutic utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (A) Superposition of the structures of HDAC1–3 (PDB (Protein Data Bank) codes: 5ICN, 4LY1 and 4A69). Significant residue differences are highlighted in cyan (HDAC1 and 2) and magenta (HDAC3). Adapted with permission from Millard 2017 [15]. (B) The active site of HDAC8 (PDB code: 4QA2). Adapted with permission from Chakrabarti 2015 [17]. (C) The foot pocket of HDAC8. Prominent amino-acid side-chain differences between HDAC8 and HDAC1 in the foot pocket are shown. Adapted with permission from Whitehead 2011 [64].](/paper-figures/b302b31d8cb448dbb4268c0b97574b20/structure-based-inhibitor-discovery-of-class-i-histone-deacetylases-hdacs-figure-2.jpg)
![Figure 3 Possible mechanism of catalysis by HDAC8. Adapted with permission from Porter 2019 [66].](/paper-figures/30fe6dccef0d4b9c92dfc9c2bf38e523/structure-based-inhibitor-discovery-of-class-i-histone-deacetylases-hdacs-figure-3.jpg)
![Figure 4 (A) Structure of the core NuRD complex (HDAC1/RBBP4/MTA1 (162-546)). Adapted with permission from Millard 2016 [75]. (B) Substructure of the Sin3 complex. Adapted with permission from Banks 2020 [80]. (C) Structure of the CoREST complex. Adapted with permission from Song 2020 [87]. (D) Structure of the MiDAC complex in dimeric form. Adapted with permission from Turnbull 2020 [89]. (E) Structure of the SMRT/NCoR complex. Adapted with permission from Oberoi 2011 [93].](/paper-figures/bf6ab3fd093741d9854ccd0d56471d17/structure-based-inhibitor-discovery-of-class-i-histone-deacetylases-hdacs-figure-4.jpg)
![Figure 5 (A) The binding site of inositol phosphate with HDAC3-SMRT complex. The inositol phosphate is shown as a stick model. Adaptedwith permission from Watson 2012 [94]. (B) Relative position of the allosteric site and binding rail on HDAC2. Adapted with permission from Zhou 2017 [96].](/paper-figures/631fbed22d954b019cbe326c9840b7de/structure-based-inhibitor-discovery-of-class-i-histone-deacetylases-hdacs-figure-5.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the development of selective inhibitors has advanced significantly.488–490”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [488]
The cited source says what the claim attributes to it.
In the citing paper
“Given the association of pan-inhibitors with cytotoxicity and adverse events”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [488]
The cited source says what the claim attributes to it.
In the citing paper
“One of the major challenges, however, in targeting HDACs 1–3 is due to their existence in multimeric states and they are often complex with other co-factors that perform different functions [6].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 6×
“In neurological diseases, HDACis can induce neuroprotection and the expression of neurotrophins [8,27].”
BackgroundInfluentialNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Advances in targeting histone deacetylase for treatment of solid tumors
Shi, M.-Q., Xu, Y., Fu, X., Pan, D., Lu, X., Xiao, Y., & Jiang, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01551-8 · Cited by 184
Shetty, M. G., Pai, P., Deaver, R. E., Satyamoorthy, K., & Babitha, K. S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105695 · Cited by 77
Histone deacetylases and their inhibitors in inflammatory diseases
Zhang, S.-Y., Zhang, L., Wen, R., Yang, N., & Zhang, T. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117295 · Cited by 72
Metadata
- Authors
- Luo, Y., & Li, H.
- Affiliations
- Sun Yat-sen University (CN)
- Corresponding author
- Li, Huilin
- ORCID
- Li, Huilin
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-11-22
- Volume
- 21
- Issue
- 22
- Pages
- 8828
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7700698
- OpenAlex
- W3108284227
- Cited by
- 62
- References
- 168
- Citations by year
- 2026: 15 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 5 · 2021: 8
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (91953102)
- Guangdong Nature Science Foundation (2019A1515011265)
- Fundamental Research Funds for the Sun Yat-sen Universities (19ykzd26)
- the Pearl River Talent Recruitment Program (2019QN01Y299)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- class I histone deacetylases, histone deacetylase inhibitors, structure-based drug design, isoform selectivity, epigenetic therapy, HDAC8, protein complexes, inhibitor specificity
- MeSH terms
- Animals, Histone Deacetylases, Humans, Protein Conformation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). https://app.cochat.ai/papers/10.3390/ijms21228828
- The paper
- Luo, Y., & Li, H. (2020). Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21228828
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.